VBI Vaccines (VBIV) Stock Price Down 6.4%

Share on StockTwits

VBI Vaccines (NASDAQ:VBIV)’s share price fell 6.4% during mid-day trading on Friday . The company traded as low as $3.52 and last traded at $3.52. 1,155,900 shares changed hands during trading, an increase of 580% from the average session volume of 170,012 shares. The stock had previously closed at $3.76.

A number of research firms have issued reports on VBIV. ValuEngine upgraded VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Zacks Investment Research downgraded VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Wednesday, May 30th. BMO Capital Markets lifted their price target on VBI Vaccines from $11.00 to $13.00 and gave the company an “outperform” rating in a research note on Thursday, May 10th. Finally, Noble Financial reiterated a “buy” rating on shares of VBI Vaccines in a research note on Friday, March 23rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $9.42.

The company has a quick ratio of 3.72, a current ratio of 3.77 and a debt-to-equity ratio of 0.11.

VBI Vaccines (NASDAQ:VBIV) last posted its earnings results on Tuesday, May 1st. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.03). VBI Vaccines had a negative return on equity of 47.54% and a negative net margin of 4,607.13%. The firm had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.21 million. sell-side analysts anticipate that VBI Vaccines will post -0.79 earnings per share for the current year.

In other news, CEO Jeff Baxter bought 11,000 shares of the company’s stock in a transaction on Thursday, May 24th. The shares were purchased at an average price of $2.99 per share, with a total value of $32,890.00. Following the transaction, the chief executive officer now directly owns 163,355 shares in the company, valued at $488,431.45. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Francisco Diaz-Mitoma bought 10,000 shares of the company’s stock in a transaction on Friday, May 11th. The shares were purchased at an average cost of $3.05 per share, for a total transaction of $30,500.00. Following the transaction, the insider now owns 268,839 shares in the company, valued at $819,958.95. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 28,100 shares of company stock worth $84,051. Insiders own 54.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC lifted its position in shares of VBI Vaccines by 47.2% during the 4th quarter. Perceptive Advisors LLC now owns 9,665,843 shares of the biopharmaceutical company’s stock worth $41,273,000 after buying an additional 3,100,000 shares in the last quarter. BVF Inc. IL bought a new position in shares of VBI Vaccines during the 4th quarter worth approximately $13,237,000. BlackRock Inc. lifted its position in shares of VBI Vaccines by 63.7% during the 4th quarter. BlackRock Inc. now owns 1,509,286 shares of the biopharmaceutical company’s stock worth $6,445,000 after buying an additional 587,036 shares in the last quarter. Meitav Dash Investments Ltd. bought a new position in shares of VBI Vaccines during the 4th quarter worth approximately $4,664,000. Finally, Sphera Funds Management LTD. bought a new position in shares of VBI Vaccines during the 4th quarter worth approximately $3,416,000. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply